Ascend Wellness Holdings (AAWH) Non-Current Debt (2020 - 2026)
Ascend Wellness Holdings (AAWH) recorded quarterly Non-Current Debt of $292.3 million in Q1 2026, little changed quarter-over-quarter from $291.1 million in Q4 2025, and up 16.18% on a YoY basis from $251.6 million in Q1 2025.
Ascend Wellness Holdings (AAWH) Non-Current Debt (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Non-Current Debt history runs 7 years deep, the most recent figure standing at $292.3 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 16.18% year-over-year to $292.3 million; the TTM figure through Mar 2026 stood at $292.3 million (up 16.18% YoY), while the FY2025 annual figure was $291.1 million, up 35.76% from the prior year.
- Non-Current Debt was $292.3 million for Q1 2026 at Ascend Wellness Holdings, roughly flat from $291.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $343.7 million in Q3 2025 to a low of $214.4 million in Q4 2024.
- Historically, Non-Current Debt has averaged $286.1 million across 5 years, with a median of $291.1 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 169.31% in 2022, then slipped 27.94% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $319.3 million in 2022, then decreased by 6.81% to $297.6 million in 2023, then retreated by 27.94% to $214.4 million in 2024, then soared by 35.76% to $291.1 million in 2025, then advanced by 0.41% to $292.3 million in 2026.
- The last three Non-Current Debt figures came in at $292.3 million (Q1 2026), $291.1 million (Q4 2025), and $343.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 569.60 Mn |
| 10 | Ascend Wellness Holdings | - | - | 44.88 Mn | 292.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 292.31 Mn |
| Mar 31, 2026 | 292.31 Mn |
| Dec 31, 2025 | 291.10 Mn |
| Dec 31, 2025 | 291.10 Mn |
| Sep 30, 2025 | 343.75 Mn |
| Sep 30, 2025 | 343.75 Mn |
| Jun 30, 2025 | 323.44 Mn |
| Jun 30, 2025 | 323.44 Mn |
| Mar 31, 2025 | 251.61 Mn |
| Mar 31, 2025 | 251.61 Mn |
| Dec 31, 2024 | 214.42 Mn |
| Dec 31, 2024 | 214.42 Mn |
| Sep 30, 2024 | 232.16 Mn |
| Sep 30, 2024 | 232.16 Mn |
| Jun 30, 2024 | 289.53 Mn |
| Jun 30, 2024 | 289.53 Mn |
| Mar 31, 2024 | 288.70 Mn |
| Mar 31, 2024 | 288.70 Mn |
| Dec 31, 2023 | 297.57 Mn |
| Dec 31, 2023 | 297.57 Mn |